Grifols(GRFS) - 2024 Q3 - Earnings Call Presentation

Financial Performance - Revenue reached €1793 million, a 124% increase at constant currency compared to the previous year[13] - Adjusted EBITDA was €462 million, with a margin of 258%, representing a 267% increase at constant currency[13] - Free cash flow amounted to €127 million, a €97 million improvement[13] - Leverage ratio improved to 51x, down from 68x in Q1 2024[13] - Year-to-date revenue reached €5237 million, an increase of 91% at constant currency[24] - Year-to-date adjusted EBITDA was €1253 million, a 250% increase at constant currency[60] Business Segment Performance - Biopharma revenue increased by 121% in Q3 2024 and 99% year-to-date at constant currency, driven by growth in core geographies and a positive product mix[24, 29] - Diagnostic revenue increased by 13% in Q3 2024 at constant currency[25] - Bio Supplies revenue increased by 487% in Q3 2024 at constant currency[95] Strategic Initiatives - GigaGen was awarded a US BARDA contract to develop its recombinant polyclonal antibody therapeutic platform[13] - The company is on track to achieve 2024 innovation milestones, including regulatory progress for Fibrinogen in the EU and the US[13, 50] - SRAAS sale proceeds of approximately €1560 million were used to reduce bonds and term loans[83]